Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and intratumoral Interleukin-2 in stage IV melanoma
NCT01480323Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Feb 2012
- Primary completion
- Sep 2014
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ipilimumab and aldesleukin in Malignant Melanoma (MM), sponsored by University Hospital Tübingen. Primary endpoint: Disease Control Rate at 12 weeks. Started Feb 2012; status: completed.
02
Drugs
ipilimumabaldesleukin
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT01480323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01480323.